Cobalis Corp. Appoints Martin Marion as Chief Executive Officer

The Board of Directors of Cobalis Corp announced the appointment of Martin Marion as Chief Executive Officer.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Irvine, CA (PRWEB) May 13, 2010

The Board of Directors of Cobalis Corp. (CLSC.PK) announced the appointment of Martin Marion as Chief Executive Officer. Mr. Marion is a seasoned strategic planning and marketing professional with a proven track record of bringing new products to market. Marion will assume responsibility to accelerate the marketing of PreHistin® – the Company’s flagship anti-allergy product – and coordinating various other revenue-generating programs.

Marion was formerly Chief Marketing Officer for Cobalis Corp, from 2003 through 2006, and has extensive knowledge of PreHistin’s competitive advantages. For the past year, Marion has consulted to the Company as Cobalis prepared to launch PreHistin® to the more than 60 million allergy sufferers in the US.
With over a 30 year career in strategic planning and healthcare marketing, Marion has served as Director of Business Development for Grey Advertising / Grey Direct; and VP, Strategic Planning and Business Development for DMB&B’s healthcare division Medicus, then the world’s largest healthcare and pharmaceutical marketing agency. He has consulted to many Tier 1 pharmaceutical marketers with an emphasis on new product introductions and competitive positioning.

Chas Radovich, Cobalis President said: “The appointment of Martin Marion as CEO adds a highly experienced marketing professional to our executive management team, and someone who can assist the Company in achieving its financial goals, with a constant view towards profitability. His extensive healthcare agency and consulting background combined with his first-hand knowledge of PreHistin® enable him to hit the ground running, and immediately commence our marketing launch strategies. We are pleased to welcome Marty back to the Cobalis family as our CEO.”

Marion added: “Cobalis holds tremendous potential, not only for PreHistin® as an entirely new approach to controlling allergies before symptoms arise, but as an innovator and marketer of preventive healthcare products. Our priority now is to quickly build a fundamental and profitable company, engage a team of best-in-class partners to execute our strategies, and thus increase shareholder value. We understand the challenges that lie ahead and our team is prepared to make the smart decisions necessary to successfully bring PreHistin® to market in the US and internationally.”

ABOUT COBALIS CORP—PREHISTIN®
Cobalis Corp. is a specialty pharmaceutical, nutraceutical and preventive healthcare product development and marketing company. Its flagship product, PreHistin®, The World’s FIRST Pre-Histamine”™, is designed to mitigate overproduction of IgE levels and restore a normal response to seasonal and year-round indoor and outdoor allergens. PreHistin® is available without prescription for both long-term and daily use.
For PreHistin® product information and ordering please visit at http://www.PreHistin.com or call toll free
1-877-4POLLEN. For additional company information please visit the corporate website at http://www.Cobalis.com.

CONTACT
Cobalis Corp.
2030 Main St., Suite 1300
Irvine, CA 92614
949-260-9007
Chas Radovich, President
Martin Marion, CEO
info (at) cobalis (dot) com
info (at) prehistin (dot) com

###


Contact

  • Martin Marion
    Cobalis Corp.
    949-260-9007
    Email

Attachments